technology

press releases

Date Title and Summary Additional Formats
Toggle Summary - Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate eptinezumab’s robust efficacy is further improved at one year following third and fourth quarterly infusions              - Approximately one-third of patients had no migraines, (achieved 100% View HTML
Toggle Summary - Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate 43% of patients receiving 300 mg of eptinezumab achieved a 75% or greater reduction of monthly migraine days - 1 in 5 patients were migraine free (achieved 100% response) on average per month View HTML
Toggle Summary New eptinezumab data at two late-breaking sessions demonstrate efficacy that is sustained and further improved after repeat treatments BOTHELL, Wash. , June 20, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic View HTML
Toggle Summary BOTHELL, Wash. , June 15, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported the grant of inducement awards to Robert (“Bob”) Azelby, effective as of June View HTML
Toggle Summary Former executive at Juno Therapeutics and Amgen, Azelby brings deep operational and commercialization expertise BOTHELL, Wash. , June 07, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals , Inc. (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the View HTML
Toggle Summary - 12-Month Data Presented at American Academy of Neurology (AAN) Annual Meeting Demonstrated Eptinezumab Further Reduced Migraine Risk Following Third and Fourth Quarterly Infusions - - Biologics License Application (BLA) Submission Expected in Q1 2019 - - Key Clinical Data Milestones, CMC Studies View HTML
Toggle Summary BOTHELL, Wash. , May 07, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Paul B. View HTML
Toggle Summary BOTHELL, Wash. , April 30, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its first quarter 2018 financial and operating results View HTML
Toggle Summary BOTHELL, Wash. , April 26, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) (“Alder” or the “Company”), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that its Board of Directors has unanimously View HTML
Toggle Summary Patients with a 75% or greater response experienced an eight-fold increase in migraine-free days and more meaningful improvements in bodily pain and physical function BOTHELL, Wash. , April 25, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company View HTML